Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06248177
Other study ID # 2023.199
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 16, 2024
Est. completion date July 30, 2024

Study information

Verified date January 2024
Source Clinica Universidad de Navarra, Universidad de Navarra
Contact Fermín Milagro Yoldi
Phone +34948425600
Email fmilagro@unav.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized clinical trial is to evaluate the effect on the microbiota and the reduction in the number and/or intensity of symptoms of gastrointestinal discomfort of consuming a probiotic or placebo for 6 weeks in adult women and men. The main questions to answer are: 1. To study changes in the alpha diversity of the microbiota. 2. To evaluate changes in the salivary cortisol. For this purpose, a randomized, double blind crossover study has been designed. Target sample size is 30 subjects. Participants will be allocated in two groups for 16 weeks (6 weeks consuming one of the products + 4 weeks wash-out period + 6 weeks consuming the other product). - Group 1 (n=15): 6 weeks daily consumption of one probiotic capsule + 4 weeks wash-out period+ 6 weeks daily consumption of one placebo capsule. - Group 2 (n=15): 6 weeks daily consumption of one placebo capsule + 4 weeks wash-out period+ 6 weeks daily consumption of one probiotic capsule.


Description:

Volunteers who wish to participate in the study will be interviewed by phone to verify that they meet the main inclusion criteria. Volunteers who meet the main inclusion criteria will be invited to an information and screening visit to resolve any doubts. Volunteers who agree to participate in the study will sign the informed consent and will be randomly allocated to one of the two arms of the study and will be provided with any required material. During the intervention, volunteers will attend 4 visits distributed in two phases of 6 weeks separated by 4 weeks of wash-out period. At the beginning and at the end of each phase there will be a clinical visit. In all visits anthropometric and body composition measurements, stool and saliva samples, as well as data about dietary and physical activity will be collected.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date July 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Volunteers of both sexes aged between 18 and 65 years old. - Volunteers with a body mass index between 18.5 and 30 kg/m2. - Present some type of discomfort/discomfort at gastrointestinal levels without having a specific diagnosis.The gastrointestinal symptoms rating scale will be used to more objectively detect these symptoms. A score between 3 and 5 in any of the symptoms will be an inclusion criterion. - Present a stable weight (+/- 3 kg) in the last three months prior to the start of the study. - Subjects must be able to understand and be willing to sign the informed consent, and must comply with all study procedures and requirements. Exclusion Criteria: - Subjects with relevant functional or structural anomalies of the digestive system, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, reflux with medication, helicobacter pylori, celiac disease and other diagnosed intolerances, etc. - Subjects with surgical interventions with permanent consequences in the digestive system (for example, gastroduodenostomy). - Subjects following treatments that alter gastrointestinal function, either chronically or occasionally. - Subjects who are being treated with antibiotics (in order to participate, they do not have to have taken antibiotics during the two months prior to the baseline visit). - Subjects with any type of cancer or undergoing treatment for it, or with less than 5 years since its eradication. - Subjects with any liver disease (may participate with non-alcoholic fatty liver disease). - Subjects with allergy to any component of the product under study. - Subjects with a high alcohol intake, more than 14 units/day (women) and 20 units/day (men). - Pregnant or breastfeeding women. - Subjects who present some type of cognitive and/or psychological impediment. - Subjects in whom poor collaboration is expected or with difficulties in following the study procedures. - Subjects who work with shift changes that include nights. - Subjects who follow any type of supplementation that interferes with the study (example: other probiotics). - Subjects who are immersed in a significant lifestyle change.

Study Design


Intervention

Dietary Supplement:
Probiotic
Probiotic capsules
Placebo
Placebo capsules

Locations

Country Name City State
Spain Centre for Nutrition Research Pamplona Navarre

Sponsors (1)

Lead Sponsor Collaborator
Clinica Universidad de Navarra, Universidad de Navarra

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fecal microbiota Fecal microbiota of participants will be analyzed by bacterial 16S gene sequencing technology. Clinical Investigation Days 1, 2, 3 and 4.
Secondary Salivary cortisol Cortisol levels will be taken by SalivetteĀ®- Cortisol kit and analyzed by electrochemiluminescence immunoassay and reported in ug/dL. Clinical Investigation Days 1, 2, 3 and 4 (at wake up in the morning, and at the same time in each Clinical investigation days).
Secondary Body weight Weight of participants will be measured by bioimpedance and reported in kg Clinical Investigation Days 1, 2, 3 and 4
Secondary Height Height of participants will be measured by stadiometer and reported in m. Clinical Investigation Day 1
Secondary Body mass index Body mass index will be calculated as follows: weight (kg)/ height (cm)2. Clinical Investigation Days 1, 2, 3 and 4
Secondary Body fat percentage Body fat of participants will be analyzed by bioimpedance and reported in percentage and kilograms. Clinical Investigation Days 1, 2, 3 and 4
Secondary Body muscle mass Body muscle mass of participants will be analyzed by bioimpedance and reported in kilograms. Clinical Investigation Days 1, 2, 3 and 4
Secondary Body lean mass Body lean mass of participants will be analyzed by bioimpedance and reported in kilograms. Clinical Investigation Days 1, 2, 3 and 4
Secondary Body water mass Body water mass of participants will be analyzed by bioimpedance and reported in kilograms. Clinical Investigation Days 1, 2, 3 and 4
Secondary Body bone mass Body bone mass of participants will be analyzed by bioimpedance and reported in kilograms. Clinical Investigation Days 1, 2, 3 and 4
Secondary Gastrointestinal symptoms Gastrointestinal symptoms will be registrated through 15 items likert questionnaire; gastrointestinal symptoms rating scale questionnaire. Clinical Investigation Days 1, 2, 3 and 4
Secondary Dietary intake Dietary intake will be analysed by food frequency questionnaire. Clinical Investigation Days 1, 2, 3 and 4
Secondary Physical activity Physical activity will be evaluated by the reduced version of the International Physical Activity Questionnaire (IPAQ). Clinical Investigation Days 1, 2, 3 and 4
Secondary Adherence to capsule consumption Adherence will be assessed using the capsule consumption record form. Clinical Investigation Days 1, 2, 3 and 4
See also
  Status Clinical Trial Phase
Withdrawn NCT03239197 - Project SHARE (motherS Have All the Right microbEs) N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT06144905 - Norwegian Microbiota Study in Anorexia Nervosa
Completed NCT05864352 - The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
Recruiting NCT04138979 - Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy
Recruiting NCT04132713 - Study on Skin Microbiome of HFS
Completed NCT05726435 - Effects of Soluble Dietary Fiber on Sport Efficiency and Fatigue Delay in Top Basketball Players N/A
Recruiting NCT02695784 - Probiotics After Discharge Phase 4
Completed NCT03543891 - Intestinal Microbiota and Thyroid Cancer
Completed NCT05242913 - Effects of Resistant Potato Starch on the Gut Microbiota N/A
Recruiting NCT04200521 - The Effect of Bariatric Procedures on Gut Microbiota in Obese Individuals in United Arab Emirates and Lebanon
Recruiting NCT05891977 - Effect of Tomato Paste Consumption on the Microbiota-gut-brain Axis in Healthy Adults N/A
Completed NCT02988349 - Ecological Effect of Arginine Dentifrice on Oral Microbiota N/A
Completed NCT05352724 - Clinical Trial to Evaluate the Efficacy of a Sport Drink After High-intensity Aerobic Exercise N/A
Completed NCT04674839 - The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals N/A
Completed NCT03754504 - Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05394948 - Circular Economy and the Design of Healthy and Sustainable Food and Ingredients N/A
Terminated NCT03752372 - Microbiome Alterations in IL10RA-deficient Patients After HSCT
Completed NCT05974124 - Effectiveness of Ophthalmic Antiseptic Preparations N/A
Recruiting NCT02005003 - Cognitive and Metabolic Effects of a Probiotic Supplement N/A